drugset
drugset / Trial / NCT05169437

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437 ↗

Phase 2 Terminated 22 enrolled Tempus AI GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.

Timeline

Start
2022-03-15
Primary completion
2024-08-06
Completion
2024-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Niraparib Small molecule — —

Indications

breast neoplasm endometrial cancer esophageal cancer head and neck cancer lung neoplasm malignant colon neoplasm malignant pancreatic neoplasm malignant urinary system neoplasm melanoma metastatic malignant neoplasm